These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8892904)

  • 1. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.
    Weber J; Fenyö EM; Beddows S; Kaleebu P; Björndal A
    J Virol; 1996 Nov; 70(11):7827-32. PubMed ID: 8892904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.
    Kostrikis LG; Cao Y; Ngai H; Moore JP; Ho DD
    J Virol; 1996 Jan; 70(1):445-58. PubMed ID: 8523557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
    Louisirirotchanakul S; Beddows S; Cheingsong-Popov R; Shaffer N; Mastro TD; Auewarakul P; Likanonsakul S; Wasi C; Weber J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):315-20. PubMed ID: 9833739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
    Simek MD; Rida W; Priddy FH; Pung P; Carrow E; Laufer DS; Lehrman JK; Boaz M; Tarragona-Fiol T; Miiro G; Birungi J; Pozniak A; McPhee DA; Manigart O; Karita E; Inwoley A; Jaoko W; Dehovitz J; Bekker LG; Pitisuttithum P; Paris R; Walker LM; Poignard P; Wrin T; Fast PE; Burton DR; Koff WC
    J Virol; 2009 Jul; 83(14):7337-48. PubMed ID: 19439467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotyping of HIV type 1 infections: definition, relationship to viral genetic subtypes, and assay evaluation. UNAIDS Network for HIV-1 Isolation and Characterization.
    Cheingsong-Popov R; Osmanov S; Pau CP; Schochetman G; Barin F; Holmes H; Francis G; Ruppach H; Dietrich U; Lister S; Weber J
    AIDS Res Hum Retroviruses; 1998 Mar; 14(4):311-8. PubMed ID: 9519892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. WHO Network for HIV Isolation and Characterization.
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1327-43. PubMed ID: 7545977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies.
    Polonis VR; De Souza MS; Chanbancherd P; Chantakulkij S; Jugsudee A; Loomis-Price LD; Vancott TC; Garner R; Markowitz LE; Brown AE; Birx DL
    AIDS Res Hum Retroviruses; 2001 Jan; 17(1):69-79. PubMed ID: 11177385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization.
    Cheingsong-Popov R; Lister S; Callow D; Kaleebu P; Beddows S; Weber J
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1379-86. PubMed ID: 7888191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype.
    Mascola JR; Louwagie J; McCutchan FE; Fischer CL; Hegerich PA; Wagner KF; Fowler AK; McNeil JG; Burke DS
    J Infect Dis; 1994 Jan; 169(1):48-54. PubMed ID: 8277197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.
    Polonis VR; de Souza MS; Darden JM; Chantakulkij S; Chuenchitra T; Nitayaphan S; Brown AE; Robb ML; Birx DL
    J Virol; 2003 Aug; 77(15):8570-6. PubMed ID: 12857927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining neutralization serotypes of HIV type 1 by neural networks.
    Kostrikis LG; Michalopoulou ZH; Cao Y; Moore JP; Ho DD
    AIDS Res Hum Retroviruses; 1996 Dec; 12(18):1667-9. PubMed ID: 8959241
    [No Abstract]   [Full Text] [Related]  

  • 15. Multivariate analysis of human immunodeficiency virus type 1 neutralization data.
    Nyambi PN; Nkengasong J; Lewi P; Andries K; Janssens W; Fransen K; Heyndrickx L; Piot P; van der Groen G
    J Virol; 1996 Sep; 70(9):6235-43. PubMed ID: 8709250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization.
    De Wolf F; Hogervorst E; Goudsmit J; Fenyö EM; Rübsamen-Waigmann H; Holmes H; Galvao-Castro B; Karita E; Wasi C; Sempala SD
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1387-400. PubMed ID: 7888192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid genetic characterization of HIV type 1 strains from four World Health Organization-sponsored vaccine evaluation sites using a heteroduplex mobility assay. WHO Network for HIV Isolation and Characterization.
    Bachmann MH; Delwart EL; Shpaer EG; Lingenfelter P; Singal R; Mullins JI
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1345-53. PubMed ID: 7888187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.
    Moore JP; Cao Y; Leu J; Qin L; Korber B; Ho DD
    J Virol; 1996 Jan; 70(1):427-44. PubMed ID: 8523556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B.
    Kitabwalla M; Ferrantelli F; Wang T; Chalmers A; Katinger H; Stiegler G; Cavacini LA; Chou TC; Ruprecht RM
    AIDS Res Hum Retroviruses; 2003 Feb; 19(2):125-31. PubMed ID: 12639248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.